New Guidance on Investigational Medicinal Products (IMPs) and Non Investigational Medicinal products (NIMPs)
The EU Commission has published a revision of the Guidance on Investigational Medicinal Products (IMPs) and Non investigational Medicinal Products (NIMPs), which had been published in 2007, completing the detailed guidance CT-1. The main change relates to point 3.3 and the additional annex 2 setting out documentation requirements for NIMPs in the application dossier.
In 3.3., it is pointed out that documentation requirements in the application dossier for IMPs also apply to NIMPs. However, depending on the knowledge of the NIMP, documentation can be reduced to a so called 'simplified dossier' described in detail in Annex 2 of the document. To determine the required data, a risk-based approach needs to be applied.
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
08.09.2025Latest Information on the EMA's Clinical Trials Information System (CTIS)
03.09.2025WHO Guidelines on Reducing Animal Testing
27.08.20253R - A Global Approach with Implications for the Pharmaceutical Industry
17.07.2025ICH E20 Draft Guideline on Adaptive Design for Clinical Trials
17.07.2025Update on ICH Guidelines E21 & E22